An Open-Label, Prospective, Multicenter, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2017
At a glance
- Drugs Human skin replacement (Primary)
- Indications Foot ulcer
- Focus Adverse reactions; First in man
- Sponsors Stratatech
- 17 Jan 2017 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
- 17 Jan 2017 Planned primary completion date changed from 1 May 2018 to 1 Apr 2019.
- 17 Jan 2017 Planned initiation date changed from 1 Apr 2016 to 1 Oct 2017.